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ORIGINAL ARTICLE
Size-Dependent Ability of Liposomes to Accumulate in the
Ischemic Myocardium and Protect the Heart
Rinat A. Mukhamadiyarov, PhD,* Evgeniya A. Senokosova, MSc,* Sergey S. Krutitsky, MD,*
Darya V. Voevoda, MSc,† Inna A. Pyshnaya, PhD,‡ Vladimir V. Ivanov, PhD,§
Martin J. Lewis, MB, BChir, FRCA,¶ and Igor Khaliulin, PhD¶
Abstract: Liposomes have the potential to be used for drug
delivery. Meanwhile, liposome size may affect their accumulation
in the target tissue. We investigated the myocardial accumulation of
2 populations of liposomes (;70 and 110 nm diameter) during
ischemia and their effect on ischemia/reperfusion injury. Isolated
rat hearts were subjected to 30 minutes of low-ﬂow ischemia with
the liposomes, followed by 30 minutes of liposome-free reperfusion.
The liposomes were loaded with the ﬂuorescent dye Nile Red to
assess their accumulation in the myocardium. The cardiac functional
recovery during reperfusion was evaluated using force–velocity
characteristics and coronary ﬂow (CF). Reperfusion injury was
evaluated by lactate dehydrogenase release. In addition, CF and
contractility were assessed in hearts perfused normally with 70 nm
liposomes. There was a 6- and 4-fold greater accumulation of the
small liposomes in the myocardium and mitochondria, respectively,
compared with the large liposomes. Importantly, even without any
incorporated drugs, both populations of liposomes improved func-
tional recovery and reduced lactate dehydrogenase release. However,
the smaller liposomes showed signiﬁcantly higher protective and
vasodilatory effects during reperfusion than the larger particles.
These liposomes also increased CF and contractility during normal
perfusion. We suggest that the protective properties of the liposomes
could be related to their membrane-stabilizing effect.
Key Words: drug delivery, heart, size of liposomes, myocardial
accumulation and distribution, cardiac ischemia/reperfusion injury,
cardioprotection
(J Cardiovasc Pharmacol 2018;72:143–152)
INTRODUCTION
There is signiﬁcant scientiﬁc interest in the potential of
liposomes to provide targeted delivery of drugs to damaged
areas of the myocardium after myocardial infarction. This
interest stems from the substantial contribution of cardiovas-
cular diseases (CVD) to morbidity and mortality and the
consequent need to derive novel treatment strategies.1 Con-
temporaneously, there has been remarkable success in the
development of targeted drug delivery using liposomes for
the treatment of oncologic pathology.2
Accumulated information and technological advances
in the development of different types of liposomes, the
possibility of incorporation of different biologically active
compounds in these particles, and their high transport ability
opens new horizons in the creation of novel highly effective
pharmacological interventions for the treatment of CVD. A
wide variety of biologically active compounds, such as
cytokine inhibitors, hormones, enzymes, signaling molecules,
and antioxidants among others, have been found to have
potential therapeutic value in the management of CVD.
However, new pharmacokinetic approaches are necessary
for these compounds to produce a beneﬁcial effect. This may
include ensuring drug delivery to a therapeutic target,
protection of these medicines against biodegradation, and
prolonged retention in the circulation.3–5 Various nanopar-
ticles are being investigated in the search for a means of
targeted drug delivery. Liposomes are probably one of the
most promising particles in this respect. Once incorporated
in liposomes, drugs can easily penetrate cellular membranes
and enter the target cells.6 However, the transport capability
of liposomes depends on their characteristics, such as the lipid
composition of the liposomal membranes, their size, charge,
various modiﬁcations of the liposomal surface, and inclusion
of target molecules. Any modiﬁcation of the liposomes mod-
ulates their properties, their interaction with cells, and efﬁcacy
of drug delivery.7,8
Importantly, pores can be formed in the capillaries
located in the area of inﬂammation that can be caused by
different pathological processes, including myocardial ische-
mia. These pores may become large enough allowing nano-
particles to penetrate the vascular barrier and accumulate in
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the affected area. This phenomenon is called the passive
targeting of nanoparticles.9 The liposomes should be small
enough to be able to implement this effect in the area of
inﬂammation. It has been found that, to accumulate in the
ischemic area, the nanoparticles should not exceed 200
nm.8,10 However, reducing the size of the liposomes may
impair their ability to accommodate drugs that need to be
delivered to the affected area. Consequently, the choice of
the size of nanoparticles as a means of transport is of critical
importance. Therefore, in this work, we studied the ability of
liposomes of different sizes to accumulate in the myocardium
during ischemia to identify the optimal size of these particles
for targeting the damaged area of the heart.
A number of agents have been found to be cardiopro-
tective when applied before ischemia. However, it is worth
mentioning that the clinical relevance of this kind of
intervention is currently restricted to cardiac surgery with
cardio-pulmonary bypass as the onset of ischemia is predict-
able in advance. Clearly, salvation of the myocardium during
perfusion in patients in whom acute myocardial ischemia has
already taken place has a broader clinical relevance.11 Fur-
thermore, the passive targeting may contribute to a greater
efﬁciency of liposome-assisted drug delivery before reperfu-
sion rather than before ischemia. Consequently, in the present
work, we assessed the accumulation of liposomes of different
sizes in the myocardium and evaluated their effect on ische-
mia/reperfusion (I/R) injury.
METHODS
Preparation and Characterization of
Liposomes
Liposomes were prepared by extrusion (extruder sup-
plied by Lipex Biomembranes Inc, Vancouver, BC, Canada)
of a suspension of multilamellar vesicles through polycar-
bonate ﬁlters.12
The composition of the lipid ﬁlm included egg lecithin
(Avanti Polar Lipids, Inc, Alabaster, AL) and cholesterol
(Sigma-Aldrich, St. Louis, MO) in the molar ratio of 7:5. To
prepare the liposomes containing a luminescent probe, Nile
Red (Molecular Probes, Eugene, OR) dye was additionally
injected. The molar ratio of lecithin:cholesterol:Nile Red was
7:5:0.015. Because Nile Red is a lipophilic dye and strongly
preserved in a nonpolar region of the liposomal membrane, it
can serve as a speciﬁc marker of liposomes.13,14 The lipo-
philic components were dissolved in chloroform and placed
in the ﬂask of a vacuum evaporator. After solvent removal,
the lipid ﬁlm obtained on the walls of the ﬂask was hydrated
with 0.9% NaCl (Sigma-Aldrich) solution by shaking to form
multilamellar vesicles. To improve hydration, the vesicles
were subjected 10 times to a freeze–thaw cycle.
This suspension was passed through the extruder using
polycarbonate ﬁlters (Corning/Costar, Corning, NY) with
pore sizes of 100 or 30 nm. The resulting preparation was
diluted with 0.9% NaCl solution to a lipid concentration of 10
mg/mL.
The size (Z-average diameter, nm) and the polydisper-
sity index (PdI) of the particles in the resulting suspension
were determined as an average of 3 measurements for each
group of the liposomes using the nanosizer Zetasizer Nano
ZS90 (Malvern Instruments Ltd, Malvern, United Kingdom).
Pdl is a measure of the distribution of the size of liposomes in
a given sample containing the particles. This parameter
reﬂects the width of the overall distribution of particle sizes
(Fig. 1).
Heart Perfusion by Langendorff
All procedures conformed to the Animals (Scientiﬁc
Procedures) Act, 1986 of the United Kingdom Parliament,
Directive 2010/63/EU of the European Parliament and the Guide
for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No. 85-23,
revised 1996). Ethical approval was granted by the Animal
Welfare and Ethics Committee of the Research Institute for
Complex Issues of Cardiovascular Diseases, SB RAS, Russia.
Experiments were performed on male Wistar rats
weighing 250–300 g. The animals were anaesthetized with
intraperitoneal thiopental (50 mg/kg). Sternotomy was then
performed; the hearts were excised and then arrested by a brief
immersion in ice-cold Krebs–Henseleit buffer (KH) contain-
ing (mM) the following: 118 NaCl, 25 NaHCO3, 4.8 KCl, 1.2
KH2PO4, 1.2 MgSO4, 11 glucose, and 1.2 CaCl2 (chemicals
were supplied by Sigma-Aldrich). Following the extraction of
the hearts, they were perfused in the Langendorff mode with
KH gassed with 95% O2 - 5% CO2 at 378C and pH 7.4. The
perfusion pressure was maintained at 60 mm Hg.
Force–velocity characteristics, ie, force of contraction
(Fcontr), speed of contraction (Vcontr) and speed of relaxation
(Vrelax), were monitored at a baseline tension of 2 g
throughout the experiment using a tension-recording system,
custom designed by the Research and Innovation Enterprise
“Topaz” (Tomsk, Russia). Lactate dehydrogenase (LDH)
activity in the efﬂuent perfusate was measured spectrophoto-
metrically at the wavelength of 340 nm using the method
previously described.15
Experimental Protocol
After 15 minutes of equilibration, the force–velocity
characteristics of the heart and coronary ﬂow (CF) were
measured, and the efﬂuent perfusate was collected for mea-
suring LDH activity. Then, normal perfusion was halted and
replaced by a period of 30 minutes of normothermic low-ﬂow
ischemia (LFI). LFI was performed by perfusing the heart
with nonoxygenated saline solution (0.9% NaCl), with or
without the liposomes, using a peristaltic pump at a rate of
0.1 mL/min (less than 1% of the CF measured at the end
of the equilibration period). LFI was followed by 30 minutes
of reperfusion with KH. After 10 minutes of reperfusion, the
CF was measured, and at 20 minutes, force–velocity char-
acteristics were recorded. Efﬂuent perfusate was also col-
lected at 20 minutes of reperfusion for analysis of LDH
activity. The efﬂuent perfusate (both with and without lip-
osomes) was discarded at all stages of the experiment.
Groups of Hearts
The hearts were randomly divided into 3 groups
according to the composition of the solution injected during
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LFI. In the Control group, hearts were injected with non-
oxygenated saline solution. Two other groups of hearts were
injected with the saline solution containing liposomes of
different size, depending on the ﬁlters used for their
preparation: the group L100 contained hearts that were
hypoperfused with the population of liposomes prepared
using the ﬁlters with 100 nm pore diameter, whereas hearts
in the L30 group were treated with the population of
liposomes prepared using the ﬁlters with 30 nm pore
diameter. Nonoxygenated saline solution was chosen to
minimize the effects of LFI itself on the pathogenesis of
ischemic injury, which includes acidosis, lack of oxygen, and
energy substrates.16 The characteristics of the 2 groups of
liposomes, L30 and L100, are described in the Results
section.
An additional series of experiments was performed to
assess the effect of liposomes delivered during normal heart
perfusion (at the constant perfusion pressure of 60 mm Hg
with oxygenated KH) on the force–velocity characteristics
and CF. After 15 minutes equilibration period, the heart
perfusion was continued with L30 at a concentration of 75
mg/mL for 30 minutes. The force–velocity characteristics and
CF were measured at the end of the equilibration period and
at 30 minutes of perfusion with the liposomes.
Evaluation of Liposome Accumulation by the
Heart
After 30 minutes of LFI with saline solution with or
without the liposomes containing Nile Red and 10 minutes of
reperfusion, the surface ﬂuorescence of the myocardium was
measured using the LAKK-M 2 laser diagnostic complex
(Research and Production Enterprise SPE “LAZMA,” Mos-
cow, Russia) by placing the ﬂuorescence detection sensor on
the surface of the right ventricle (Fig. 2). Then, the heart was
removed from the aortic cannula and frozen in liquid nitro-
gen. The apex of the heart was cut off; cryosections of 10–
12 mm were prepared using the Microm HM 525 cry-
omicrotome (Thermo Scientiﬁc, Waltham, MA) and placed
on slides coated with L-polylysine (Menzel Glaser,
Braunschweig, Germany). The sections were stained with
DAPI nuclear stain (Sigma-Aldrich) at a concentration of 10
mg/mL and incubated for 30 minutes at room temperature.
The prepared sections were placed into ProLong mountant
(Life Technologies, Camarillo, CA) under the coverslip.
These preparations were then analyzed using a confocal laser
scanning microscope LSM 700 (Carl Zeiss, Aalen, Germany).
For quantiﬁcation of the content of Nile Red–loaded
liposomes in the myocardium, 250 mg of samples were
used. The tissue was ground under liquid nitrogen, and Nile
Red was extracted by incubation in 2.5 mL of isopropyl
alcohol, in the dark, at a temperature of +68C for 72 hours.
After 30 minutes of centrifugation at 3000g, the ﬂuorescence
of the extracts (Ex/Em 530/570 nm) was measured using
a Varian Cary Eclipse spectroﬂuorometer (Varian Medical
Systems, Palo Alto, CA).
To assess the accumulation of liposomes in mitochon-
dria during LFI, evaluation of Nile Red ﬂuorescence was
performed in the mitochondrial fraction in the groups of
hearts loaded with the ﬂuorescent probe (ie, the groups L100
+NR and L30+NR) and compared with the level of ﬂuores-
cence of the mitochondria isolated from the Control hearts
hypoperfused with saline solution only.
Isolation of Mitochondria and Determination
of Liposomal Label
Mitochondria were obtained from 1 g pieces of the
heart apex by differential centrifugation (ultracentrifuge
Optima MAX-XP; Beckman Coulter, Indianapolis, IN).17
The isolated mitochondria were resuspended and extracted
in 2.5 mL of isopropyl alcohol (Sigma-Aldrich). Nile Red
ﬂuorescence was then measured by a Varian Cary Eclipse
spectroﬂuorometer.
Statistical Analysis
Data are presented as mean 6 SEM. Statistical signiﬁ-
cances of the differences between groups were evaluated by
1-way ANOVA followed by Tukey’s multiple comparison
post hoc test. The differences between the parameters mea-
sured during the equilibration period and reperfusion (or nor-
mal perfusion with the liposomes) in the same hearts of each
group were assessed using 2-tailed paired Student’s t test. The
statistical analysis was performed using software Statistica,
Version 6.0 (TIBCO, Palo Alto, CA). Differences were con-
sidered statistically signiﬁcant where P , 0.05.
RESULTS
Characterization of the Liposomes
The characteristics of liposomes of different groups are
presented in Table 1. Extrusion of the multilamellar vesicles
through ﬁlters with a pore diameters of 100 nm (L100) or 30
nm (L30) led to the formation of 2 populations of liposomes
with an average diameter of ;110 and 70 nm, respectively.
The maximum and the minimum size of the liposomes of
these groups were also different (Table 1). The distribution
of sizes in the L100 and L30 groups, with and without the
ﬂuorescent dye Nile Red, was assessed by calculating PdI
FIGURE 1. Distribution of the size of liposomes produced
using filters with 30 or 100 nm pore diameters (groups L30
and L100). 1, L30; 2, L100; 3, L30+NR; 4, L100+NR. The
presented size measurements are the average of 3 samples
from each group of liposomes. PdI—polydispersity index (an
indication of the width of the overall distribution of sizes).
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(Fig. 1). This index was similar in groups L30 and L100.
Addition of the ﬂuorescent probe Nile Red to the liposomal
composition increased PdI in liposomes prepared with the 30
nm ﬁlter pore (group L30+NR). However, the average size of
the liposomes, both L30 and L100, remained unchanged by
Nile Red (Table 1).
Accumulation of Liposomes in the
Myocardium During LFI
Surface ﬂuorescence of the hearts subjected to 30 minutes
of normothermic LFI with liposomes of the 2 groups, L30 and
L100, loaded with the dye Nile Red showed a remarkably high
accumulation of L30 in the myocardium. The ﬂuorescence of
hearts treated with L30+NR was 6-fold higher than that in
hearts of L100+NR group (Fig. 3A; P , 0.05).
The level of ﬂuorescence of the isopropanol extracts
obtained from the hearts homogenized after LFI showed
a similar extent of differences between the groups L30+NR,
L100+NR, and Control. Fluorescence of the L100+NR group
was signiﬁcantly higher than that in the Control (P , 0.05),
whereas ﬂuorescence of the L30+NR group signiﬁcantly ex-
ceeded the ﬂuorescence of both Control and L100+NR
groups (Fig. 3B; P , 0.05). These differences were also
TABLE 1. Characteristics of the Groups of Liposomes
Groups of
Liposomes
Composition of the
Lipid Phase of the
Liposomes. Molar
Ratio of PC:C:NR
Diameter of the Filter
Pores Used for
Extrusion (nm)
Minimum Diameter of
the Liposomes (nm)
Maximum Diameter of
the Liposomes (nm)
Z-Average Diameter of
the Liposomes (nm)
L100 7:5:0 100 59 255 113.20 6 4.06
L30 7:5:0 30 33 164 67.17 6 2.97
L100+NR 7:5:0.015 100 51 255 111.75 6 4.45
L30+NR 7:5:0.015 30 33 164 66.82 6 4.10
The data shown in the table were calculated from 3 measurements for each group of liposomes. The dye Nile Red had no effect on the size of liposomes. Please see the distribution
of liposome sizes in Figure 1.
C, cholesterol; L30 and L100, liposomes produced with ﬁlters of 30 and 100 nm; NR, Nile Red; PC, phosphatidylcholine.
FIGURE 3. Accumulation of liposomes in the myocardium
loaded with the dye Nile Red (NR) during LFI. Liposomes
accumulation was measured at 10 minutes of reperfusion. Axis
Y—fluorescence intensity of Nile Red. Groups of hearts: Con-
trol (n = 6), L30+NR (n = 6), and L100+NR (n = 6). Panel A—
surface fluorescence in the hearts after 30 minutes of LFI. Panel
B—fluorescence of the hearts homogenized after 30 minutes
of LFI. *P , 0.05 versus Control; #P , 0.05 versus L100+NR.
FIGURE 2. Measurement of surface fluorescence of the heart
loaded with the dye Nile Red. A heart loaded with Nile Red
was perfused in the Langendorff mode. The fluorescence
detection head was placed against the surface of the right
ventricle.
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obvious in the confocal images. Thus, the level of ﬂuores-
cence of the Control hearts, hypoperfused with the saline
solution, was very low (Fig. 4A). However, after LFI with
L100 and L30 loaded with Nile Red, the level of ﬂuorescence
grew considerably (Figs. 4B–E). Particularly notable was the
sharp increase in ﬂuorescence in hearts hypoperfused with
L30+NR (Figs. 4C, D).
Localization and Distribution of the
Liposomes in the Myocardium
In general, the localization and distribution of the
liposomes (assessed by Nile Red ﬂuorescence) in the
myocardium was similar to hearts treated with liposomes
from each of the 2 groups. Nonhomogeneous ﬂuorescence
and the presence of bright granular structures were observed
in hearts of the L30+NR group (Figs. 4C, D). In the L100
+NR group, a weak level of ﬂuorescence (Figs. 4B, E) made
the analysis of localization of Nile Red in these hearts very
difﬁcult. In the longitudinal and transverse sections of the
hearts hypoperfused with L30, Nile Red ﬂuorescence was
located both around and inside of the cardiomyocytes (Fig. 5).
Fluorescence of the mitochondrial fraction was
observed in both groups hypoperfused with liposomes.
However, in the hearts treated with L30+NR, the level of
ﬂuorescence was 4-fold higher than that in hearts hypoper-
fused with the L100+NR group (Fig. 6).
Functional Recovery of the Hearts During
Reperfusion
Normal perfusion of hearts with oxygenated KH
containing L30 (75 mg/mL) resulted in a slight but signiﬁcant
increase in CF that was accompanied by a signiﬁcantly
increased Vrelax (Fig. 7). Fcontr and Vcontr also tended to be
elevated in these hearts during perfusion with the liposomes.
Analysis of both the recovery of contractile function and
of CF also revealed signiﬁcant differences between the groups
of hearts treated with L30 and L100 (Table 2). After LFI with
the saline solution (Control group), the force of contraction
(Fcontr) recovered to 53% of the preischemic value after 30
minutes of reperfusion. In the L100 group, this parameter recov-
ered to 67% (P. 0.05 vs. Control), and in the L30 group, Fcontr
reached 82% of the preischemic value (P , 0.05 vs. Control).
FIGURE 4. Distribution of the dye Nile Red in the myocardium after LFI with liposomes. Isolated rat hearts were subjected to 30
minutes of LFI with liposomes (L30 and L100 groups, n = 6 in each group) or with saline solution (control group, n = 6), frozen,
sectioned, loaded with the dye DAPI, and visualized using a confocal microscope (see methods). Blue fluorescence corresponds to
the nuclei dyed with DAPI. Red fluorescence corresponds to liposomes loaded with Nile Red. Panel A, Control; Panels B and E,
L100; and Panels C and D, L30.
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Recovery of the speed of contraction (Vcontr) was also
different between the groups. In the Control group, Vcontr
decreased to 37% of the preischemic value, whereas in the
L30 group, this index was twice as high as in the Control
group. In L30 hearts, Vcontr was 29% greater than that in the
hearts treated with L100 (P , 0.05). Similar differences
between the groups were observed for Vrelax (speed of relax-
ation). In the L30 group, this parameter after reperfusion
seemed to be signiﬁcantly higher compared with both Control
and L100 hearts (P , 0.05, Table 2).
The differences in CF were even greater between the
groups (Table 2). In the hearts of the Control group, CF fell
nearly 2-fold after 20 minutes of reperfusion compared with the
preischemic value. Meanwhile, in hearts hypoperfused with lip-
osomes, CF seemed to be increased even compared with the
preischemic values. In the hearts of the L100 group, this param-
eter was elevated by 20% (P , 0.05), whereas in the L30
group, CF grew by 50% of the preischemic value (P ,
0.05). This was accompanied by the lowest activity of LDH
in the efﬂuent perfusate sampled after 20 minutes of reperfu-
sion, where LDH activity in the L30 group was 2-fold lower
than that in the Control (Table 2).
DISCUSSION
The results of this study conﬁrmed the ability of
liposomes to penetrate the capillary barrier in the heart during
myocardial LFI and accumulate in the myocardium. Impor-
tantly, the degree of accumulation of liposomes depended on
their size. In our experiments, L30 (average liposome
diameter of ;70 nm) seemed to be able to accumulate in
the ischemic myocardium with a signiﬁcantly higher efﬁ-
ciency than L100 (average liposome diameter of ;110 nm).
Liposomes of a variety of sizes have been used in
studies investigating the transport of liposomes to the
myocardium. In particular, Verma et al18 used liposomes of
;170–190 nm before 30 minutes of normothermic ischemia
of isolated rat heart. In this work, the authors demonstrated
accumulation of liposomes in the area of infarction. In
another study,19 liposomes of ;130 nm containing adenosine
were administered in the bloodstream at the end of regional
ischemia. This treatment resulted in a signiﬁcant reduction of
the infarct size. Paulis et al20 have compared the distribution
of micelles (;15 nm) and liposomes (;110 nm) loaded with
a ﬂuorescent dye. They found that micelles accumulate in the
myocardium during the acute stage of infarction but can be
washed out quickly from this zone. The rate of penetration of
the liposomes to the infarcted area was slower but they re-
mained in the myocardium for longer. Previously, we have
shown the ability of liposomes of ;70 nm loaded with an-
tioxidants to attenuate I/R injury.12,21,22 Interestingly, in that
study, even the liposomes without antioxidants induced
a cardioprotective effect.
Clearly, reduction of liposome size would enhance their
effect of passive targeting to the ischemic myocardium.
However, this would inevitably diminish their capacity to
carry the drugs in either the core or in the membrane of the
liposomes. The results of our experiments conﬁrmed that the
ability of the population of relatively small liposomes,
produced by extrusion through 30 nm ﬁlters (the diameter
of most of these liposomes was ;70 nm, as seen from Table
1), to accumulate in the ischemic myocardium is signiﬁcantly
higher compared with the population of larger particles, pre-
pared using 100 nm ﬁlters (with an average liposomal diam-
eter of ;110 nm). This effect will, in our belief, need to be
FIGURE 5. Localization of liposomes
after hypoperfusion with L30. Iso-
lated rat hearts were subjected to 30
minutes of LFI with liposomes L30,
frozen, sectioned, loaded with the
dye DAPI, and visualized using
a confocal microscope (see Methods
for more details). Blue fluorescence
corresponds to the nuclei dyed with
DAPI. Red fluorescence corresponds
to liposomes loaded with Nile Red.
Panel A, Longitudinal section of
myofibrils; Panel B, transverse sec-
tion of myofibrils.
FIGURE 6. Fluorescence of Nile Red in mitochondrial fraction
of the myocardium. Isolated rat hearts were subjected to 30
minutes of LFI with liposomes (L30 and L100 groups) or with
saline solution (n = 6 in each group). After LFI, hearts were
homogenized, and mitochondria were isolated using differ-
ential centrifugation as described in Methods. *P , 0.05 ver-
sus Control.
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taken into account when the liposomes are used for targeted
drug delivery.
In our experiments, liposomes were able to preserve the
contractile function of hearts after LFI. This protective effect
of liposomes was in accord with previously published data on
the antiarrhythmic effect of liposomes. Soloviev et al23 have
shown that quercetin-ﬁlled phosphatidylcholine liposomes are
able to prevent peroxynitrite-induced cardiac arrhythmias in
the models of isolated rat papillary muscle, Langendorff-
perfused rat hearts, and anesthetized rats. Unfortunately, this
study lacked a group of “empty” liposomes (without any
additional drugs incorporated in the liposomes). However,
recently, we have found that “empty” L30, as well as L30
loaded with antioxidants (vitamin E and superoxide dismu-
tase), can effectively prevent ventricular arrhythmias when
administered intracoronary before ischemia.12 The effect of
liposomes on cardiac rhythm is an important area of research
that needs further investigation.
FIGURE 7. Effects of normal KH perfusion with
liposomes (L30) on the force–velocity character-
istics and CF. Isolated rat hearts (n = 8) were
perfused normally with oxygenated KH at 60 mm
Hg. After the 15-minute equilibration, L30 were
added to the perfusate at the final concentration
of 75 mg/mL. Fcontr (Panel A), Vcontr (Panel B),
Vrelax (Panel C), and CF (Panel D) were measured
at the end of equilibration and at 30 minutes of
perfusion with L30. *P , 0.05 versus KH perfusion
without liposomes.
TABLE 2. Effects of Low-Flow Ischemia With Liposomes of Different Sizes on the Force–Velocity Characteristics, CF, and LDH
Release During Reperfusion
Groups of Hearts
Preischemia
Fcontr (g) Vcontr (g/s) Vrelax (g/s) CF (mL/min) LDH Activity (mU/mL$1021)
Control (n = 12) 12.2 6 0.2 44.0 6 1.5 32.1 6 2.2 11.4 6 0.1 4.7 6 0.8
L100 (n = 12) 12.2 6 0.2 43.9 6 1.8 31.7 6 1.6 11.5 6 0.1 4.7 6 0.8
L30 (n = 12) 12.2 6 0.2 42.6 6 1.2 33.0 6 2.0 11.4 6 0.1 4.7 6 0.9
Groups of Hearts
Reperfusion
Fcontr (g) Vcontr (g/s) Vrelax (g/s) CF (mL/min) LDH Activity (mU/mL$1021)
Control (n = 12) 5.5 6 0.2 16.3 6 0.4 9.2 6 0.4 5.6 6 0.1 31.6 6 1.8
L100 (n = 12) 6.8 6 0.2* 19.2 6 0.8* 12.8 6 0.5* 13.8 6 0.1*,§ 25.9 6 1.5*
L30 (n = 12) 8.4 6 0.2*,# 31.9 6 2.1*,# 23.7 6 1.0*,# 17.2+0.1*,#,§ 16.5 6 1.4*,#
Control hearts were subjected to LFI with saline solution. Hearts of L100 and L30 groups were hypoperfused with liposomes produced by extrusion through ﬁlters with pore
diameter of 100 and 30 nm, respectively.
Contractile function was assessed at a baseline tension of 2 g 15 minutes into the preischemic period and at 20 minutes of reperfusion. LDH activity in the efﬂuent perfusate was
measured at the same time points as contractile function. CF was measured after 15 minutes of perfusion preischemia and again after 10 minutes of reperfusion.
All parameters in each group of hearts measured during reperfusion were signiﬁcantly different compared with the corresponding preischemic values (P , 0.05).
*P , 0.05 versus Control; #P , 0.05 versus L100; §P , 0.05—signiﬁcant increase in CF compared with preischemia.
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In contrast to hearts hypoperfused with the saline solution,
liposomes prevented the “no reﬂow” phenomenon after LFI.
The CF is usually regulated by the needs of myocardial con-
traction such that the perfusate supply is matched to its
demand.24 Accordingly, CF in Control hearts was signiﬁcantly
reduced during reperfusion. The improved postreperfusion con-
tractility in hearts of the L30 group compared with the Control
may partially explain the increased CF in these hearts. However,
this parameter was not only preserved but even signiﬁcantly
increased in the liposome-treated hearts compared with the pre-
ischemic value. Furthermore, when L30 were perfused in nor-
mal conditions in our experiments, they also increased CF
resulting in the increased contractile function of the myocar-
dium. These results imply that LFI of hearts with liposomes
in our experiments induced a vasodilatory effect that was inde-
pendent of the myocardial needs during reperfusion. Indeed, we
have shown previously that recovery of CF in hearts treated with
liposomes can be associated with increased activity of the endo-
thelial nitric oxide synthase, which brought about vasodilation
and endothelial protection by reducing lipid peroxidation.21
According to the data obtained with the laser diagnostic
complex and spectroﬂuorometric evaluation of ﬂuorescence
of the homogenized hearts, intense ﬂuorescence was observed
in Nile Red spectrum of the hearts treated with the liposomes
loaded with the dye. We therefore used Nile Red as
a liposomal label. Our results then indicate that LFI of hearts
with liposomes of either size provides successful transport of
these particles into the ischemic myocardium. Remarkably,
the accumulation of L30+NR in the ischemic myocardium
dramatically exceeded the accumulation of L100+NR. Both
methods used to evaluate uptake of the liposomes by the
tissues showed approximately a 6-fold increase in the efﬁ-
ciency of particle delivery to the myocardium when the diam-
eter of liposomes was ;70 nm compared with the ones with
the average size of 110 nm. Based on the results acquired
using confocal microscopy (Figs. 4B, E vs. Figs. 4C, D), the
ﬂuorescence of the samples in the Nile Red spectrum in the
L30+NR group was signiﬁcantly higher than that in the L100
+NR group at the same settings of the confocal microscope.
Differences in ﬂuorescence between different cardio-
myocytes were observed in heart sections from the L30+NR
group. Because in cardiomyocytes the mitochondria are local-
ized along the myoﬁbers, the observed ﬂuorescence of Nile
Red in this region can be partly provided by the labeled lip-
osomes absorbed by these organelles. To verify this assump-
tion, we isolated mitochondria from the hearts of the Control,
L30+NR and L100+NR groups and estimated the content of
Nile Red. The results from this experiment proved the pres-
ence of the labeled liposomes of both liposome-treated groups
in the mitochondria (Fig. 6). However, in the L30+NR group,
the ﬂuorescence of Nile Red was 4-fold higher than in the
L100+NR group.
The presence of the liposomal label in the mitochondria
after LFI with liposomes is of great importance because these
organelles play an important role in the mechanism of I/R
injury of the myocardium.16 Delivery of mitochondria-
targeted biologically active substances (eg, antioxidants)
may contribute signiﬁcantly to the preservation of mitochon-
dria and reduce myocardial injury in general.25
Thus, these results prove the possibility of successful
delivery of liposomes to the ischemic myocardium and that
the size of these liposomes is critical for targeted delivery to
this area of the myocardium. Indeed, to achieve the protective
effect, the liposomes must overcome the vascular barrier
formed by endotheliocytes and basal membrane and penetrate
the targeted area.26 Therefore, during systemic or local
administration of the liposomes, the effect of passive targeting
is of paramount importance.
Liposomes could be administered by intracoronary
infusion during cardiac surgery with cardioplegic arrest and
cardiopulmonary bypass or during heart preservation before
transplantation. In these cases, heart would be the only organ
where the liposomes are delivered, and these nanoparticles
would be accumulated in the affected areas of the myocar-
dium because of the effect of passive targeting. During
systemic administration of liposomes as drug carriers, they
may be degraded by macrophages, which would shorten their
circulation in the body. However, this problem can be solved
by supplementing the composition of the liposomal mem-
brane with polyethylene glycol.27
When the optimal size of the liposomes is established,
targeting of these particles can be further adjusted by
modifying their other properties. Thus, by changing the
characteristics of the liposomes, it is possible to provide not
only their targeted delivery to a certain type of cells, but also
target them to certain cellular organelles within those cells,
including the mitochondria. This can be achieved by inclu-
sion of antibodies, ligands of speciﬁc membrane receptors of
the target tissues,28 or other molecules able to target these
nanocarriers to the mitochondria.29,30 Interestingly, our data
revealed that even the ordinary nonactively-targeted lipo-
somes used in our experiments are delivered into the mito-
chondria. It would be important to study the effects of
liposomes on mitochondria because these organelles play
a crucial role not only in energy metabolism, but also in
regulation of the mechanisms of cell death and survival.16
Importantly, in our experiments, liposomes served not
only as transport containers but also as independent thera-
peutic agents. The mechanism of the cardioprotective effect
of liposomes has yet to be discovered. However, some
previously obtained data may shed light on the possible
mechanism of this effect. Our liposomes were composed of
lecithin, a mixture of glycerophospholipids (PLs), and
cholesterol, an essential structural component of biological
membranes. Küllenberg et al31 have pointed out that PLs have
a positive impact in several diseases, eg, immune or cancer
cells, apparently without severe side effects. The authors
noted that these properties of liposomes can partially be ex-
plained by the fact that PLs are highly effective in delivering
their fatty acid residues (including cholesterol) for incorpora-
tion into the membranes of cells involved in different pathol-
ogies. It can be suggested that the liposomal membrane can
act as a donor of lipids or even fragments of “membrane
patches” for damaged organelles32 and optimize the lipid bal-
ance, ameliorating the membrane damage caused by LFI in
our experiments. This membrane-stabilizing effect of lipo-
somes could also contribute to the prevention of cardiac ar-
rhythmias mentioned above.12,23 Because the uptake of L30
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by the ischemic myocardium was notably higher than that of
L100, and this was accompanied by a stronger cardioprotec-
tive effect in L30 group, we assume that the beneﬁcial effect
of liposomes in our experiments was dose dependent.
In most of the studies on the targeted delivery of
liposomes to the ischemic myocardium, liposomes equal to or
greater than 100 nm were used. This was probably associated
with the convenience of preparation of this kind of liposomes
by extrusion through polycarbonate membranes. Moreover,
liposomes of this size have a sufﬁciently large internal
volume for the delivery of biologically active substances.
However, the results presented in our study show that
reducing the particle size to ;70 nm (group L30) improves
the efﬁciency of their delivery by 6-fold compared with the
liposomes of ;110 nm (group L100).
Thus, liposomes represent a promising means of
targeted drug delivery according to the experimental data,
including the results of the present study performed on a rat
heart model. However, data obtained in the experiments on
small rodents cannot be extrapolated directly to clinical
practice. To advance the translation of these ﬁndings, experi-
ments on isolated human tissues or the large animal models
can be used. For example, porcine heart has anatomy and
physiology very similar to the human heart and ideal for the
purpose of translation.33,34
CONCLUSIONS
Taken together, our experiments reveal that the lip-
osomes composed of egg lecithin and cholesterol possess
pharmacokinetic and pharmacodynamic properties, which
make them a very promising means for the treatment of CVD.
These liposomes can accumulate in the ischemic
myocardium and induce their own protective effect against
ischemia/reperfusion injury. This protective effect is man-
ifested in better preservation of myocardial contractile
function, prevention of the no-reﬂow phenomenon, and
reduction of LDH release during reperfusion, implying that
liposomes possess a membrane-stabilizing effect. Interest-
ingly, the liposomes also induce a pronounced vasodilatory
effect in the myocardium.
Importantly, the cardioprotective and vasodilatory ef-
fects of the liposomes depend on the size of these particles:
the population of liposomes with an average diameter of ;70
nm demonstrates a more marked protection than the popula-
tion of liposomes with an average diameter of ;110 nm.
These differences of the effects of liposomes of different size
are dose dependent because the smaller particles may pene-
trate the capillaries more easily and accumulate in the ische-
mic myocardium.
A fraction of the liposomes delivered to cardiomyo-
cytes are localized in the mitochondria, which may further
potentiate the protective activity. The accumulation of these
particles in the mitochondria is also increased when the size
of liposomes is reduced. Therefore, we believe that liposomes
with an approximate diameter of 70 nm can act as an effective
transport platform for delivery of drugs to the ischemic
myocardium and may be used to create novel highly effective
pharmacological interventions.
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